HOMEVULNERABILITIESCVE-2026-5779
CRITICAL

CVE-2026-5779

CWE-284Published: April 28, 2026· Updated: Apr 28, 2026

9.4
CVSS v3.1
EPSS:0.04%probability of exploitation in 30 daysPercentile:11.4th

Official Description

An insecure direct object reference (IDOR) vulnerability in MphRx's Minerva V3.6.0, specifically in the '/minerva/user/updateUserProfile' endpoint. This allows an authenticated user to modify the information of other registered users. Successful exploitation of this vulnerability allows an authenticated user to modify other users' information, such as their email address, and request a new password via the '/webconnect/#/forgotPassword' endpoint. This could lead to complete account takeover.

NVD Source

Technical Analysis

CVE-2026-5779 can be exploited remotely over the network without requiring physical or adjacent access, significantly expanding the attack surface for threat actors.

Exploitation requires low privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorNetwork
Attack ComplexityLow
Privileges Req.Low
User InteractionNone
ScopeX
Impact
Confidentiality
Integrity
Availability
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:L/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

All References (1)

Quick Facts

CVE IDCVE-2026-5779
CVSS Score9.4 / 10
SeverityCRITICAL
WeaknessCWE-284
CISA KEVNo
EPSS (30d)0.04%
PublishedApr 28, 2026

Related CVEs (CWE-284)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2026-5779 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.